Germany · Delayed Price · Currency is EUR InMed Pharmaceuticals Statistics
Total Valuation
FRA:MWG has a market cap or net worth of EUR 4.32 million. The enterprise value is -3.19 million.
| Market Cap | 4.32M |
| Enterprise Value | -3.19M |
Important Dates
The next estimated earnings date is Thursday, February 5, 2026.
| Earnings Date | Feb 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 2.80M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +699.74% |
| Shares Change (QoQ) | +165.01% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 5.03% |
| Float | 2.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.06 |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.46 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.95, with a Debt / Equity ratio of 0.06.
| Current Ratio | 6.95 |
| Quick Ratio | 6.25 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -82.17% and return on invested capital (ROIC) is -45.70%.
| Return on Equity (ROE) | -82.17% |
| Return on Assets (ROA) | -41.59% |
| Return on Invested Capital (ROIC) | -45.70% |
| Return on Capital Employed (ROCE) | -67.15% |
| Revenue Per Employee | 314,572 |
| Profits Per Employee | -538,337 |
| Employee Count | 13 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 3.01 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.47% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -74.47% |
| 50-Day Moving Average | 1.61 |
| 200-Day Moving Average | 2.14 |
| Relative Strength Index (RSI) | 33.81 |
| Average Volume (20 Days) | 75 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.09 |
Income Statement
In the last 12 months, FRA:MWG had revenue of EUR 4.09 million and -7.00 million in losses. Loss per share was -1.77.
| Revenue | 4.09M |
| Gross Profit | 1.38M |
| Operating Income | -6.76M |
| Pretax Income | -7.00M |
| Net Income | -7.00M |
| EBITDA | -6.58M |
| EBIT | -6.76M |
| Loss Per Share | -1.77 |
Balance Sheet
The company has 7.99 million in cash and 545,679 in debt, giving a net cash position of 7.44 million.
| Cash & Cash Equivalents | 7.99M |
| Total Debt | 545,679 |
| Net Cash | 7.44M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 9.88M |
| Book Value Per Share | 2.50 |
| Working Capital | 7.88M |
Cash Flow
| Operating Cash Flow | -6.43M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 33.69%, with operating and profit margins of -165.22% and -171.13%.
| Gross Margin | 33.69% |
| Operating Margin | -165.22% |
| Pretax Margin | -171.13% |
| Profit Margin | -171.13% |
| EBITDA Margin | -160.81% |
| EBIT Margin | -165.22% |
| FCF Margin | n/a |
Dividends & Yields
FRA:MWG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -699.74% |
| Shareholder Yield | -699.74% |
| Earnings Yield | -161.99% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 14, 2024. It was a reverse split with a ratio of 0.05.
| Last Split Date | Nov 14, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
FRA:MWG has an Altman Z-Score of -12.04 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.04 |
| Piotroski F-Score | 3 |